Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

AIRS
AirSculpt Technologies, Inc. Common Stock
stock NASDAQ

At Close
Sep 29, 2026 3:59:55 PM EDT
1.81USD-3.723%(-0.07)731,344
0.00Bid   0.00Ask   0.00Spread
Pre-market
Sep 29, 2026 9:28:30 AM EDT
1.90USD+1.064%(+0.02)720
After-hours
Sep 29, 2026 4:53:30 PM EDT
1.84USD+1.657%(+0.03)10,856
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsTrends
AIRS Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
AIRS Specific Mentions
As of Sep 30, 2026 8:19:48 AM EDT (1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
43 days ago • u/Far-East-locker • r/stocks • exploring_the_glp1_aesthetics_basket • B
GPL-1 is here to stay, demand will kept growing. However at this point, i hate NVO, as it is a value trap, and i hate LLY even more, it is just too expensive. The threat of price war and patent cliff is real too. Both are just not a good entry IMO.
However, GLP-1 manufacture is not the only play.
Currently, I'm exploring companies that fix the loose skin problem with skin-tightening treatments - AIRS, INMD, APYX, ESTA, EOLS.
These few companies have been beaten down badly, as GLP-1 created the biggest headwind for clinics that do liposuction. However, they are seeing a turnaround as demand for skin-tightening treatments spikes, and it will keep growing.
Also, people are actually putting stuff back in (as crazy as it sound....) breast jobs, butt job, fat transfer to fix "Ozempic face."
Yes, these names are much more speculative, absolutely unlike NVO, which is a value play. However, I don't mind putting a small pot into some of these names, as the upside is quite high.
sentiment -0.97
43 days ago • u/Far-East-locker • r/stocks • exploring_the_glp1_aesthetics_basket • B
GPL-1 is here to stay, demand will kept growing. However at this point, i hate NVO, as it is a value trap, and i hate LLY even more, it is just too expensive. The threat of price war and patent cliff is real too. Both are just not a good entry IMO.
However, GLP-1 manufacture is not the only play.
Currently, I'm exploring companies that fix the loose skin problem with skin-tightening treatments - AIRS, INMD, APYX, ESTA, EOLS.
These few companies have been beaten down badly, as GLP-1 created the biggest headwind for clinics that do liposuction. However, they are seeing a turnaround as demand for skin-tightening treatments spikes, and it will keep growing.
Also, people are actually putting stuff back in (as crazy as it sound....) breast jobs, butt job, fat transfer to fix "Ozempic face."
Yes, these names are much more speculative, absolutely unlike NVO, which is a value play. However, I don't mind putting a small pot into some of these names, as the upside is quite high.
sentiment -0.97


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC